Loading…
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial
Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent malignant glioma. Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical...
Saved in:
| Published in: | Clinical cancer research 2005-06, Vol.11 (11), p.4160-4167 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3 |
| container_end_page | 4167 |
| container_issue | 11 |
| container_start_page | 4160 |
| container_title | Clinical cancer research |
| container_volume | 11 |
| creator | YAMANAKA, Ryuya HOMMA, Junpei TANAKA, Ryuichi YAJIMA, Naoki TSUCHIYA, Naoto SANO, Masakazu KOBAYASHI, Tsutomu YOSHIDA, Seiichi ABE, Takashi NARITA, Miwako TAKAHASHI, Masuhiro |
| description | Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent
malignant glioma.
Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical
study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood
dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432,
and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally
every 3 weeks.
Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses
were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10
patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than
the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations
had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity
responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic
cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that
in the control group.
Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients
with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients. |
| doi_str_mv | 10.1158/1078-0432.CCR-05-0120 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67893943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19730678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3</originalsourceid><addsrcrecordid>eNqFkV1rFTEQhoNYbK3-BCU3Cl5sm8nXJt7JWuuBQkup3oY0m7iRnN2a7FoEf7xZzrG9LAQyyTzzTjIvQm-AnAAIdQqkVQ3hjJ503XVDREOAkmfoCIRoG0aleF7j_8whelnKT0KAA-Ev0CEIzQgT9Aj97VIco7MJn_22abFznEY8BfzZj32Oc3S48ynh79a5OO6yYcr4qoZ-nAu-j_OAr71bcq5nfJ7itLUf601ZUk1XJYsfWlwNtni8Od1s8E2ONr1CB8Gm4l_v92P07cvZTfe1ubg833SfLhonCMyNoD2oVhLL-zZQ0BqUF4wIC0py7RVl1AepAtNBAVeaB9ErLnmwraQt3LJj9H6ne5enX4svs9nG4uq_7OinpRjZKs00Z0-CoFtGKl1BsQNdnkrJPpi7HLc2_zFAzOqPWWdv1tmb6o8hwqz-1Lq3-wbL7db3j1V7Qyrwbg_YUkcWsh1dLI-cVFQQuQp92HFD_DHcx-yNq6SvLhRvsxvqI9bFobL_AP2SpPc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19730678</pqid></control><display><type>article</type><title>Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial</title><source>Freely Accessible Journals</source><creator>YAMANAKA, Ryuya ; HOMMA, Junpei ; TANAKA, Ryuichi ; YAJIMA, Naoki ; TSUCHIYA, Naoto ; SANO, Masakazu ; KOBAYASHI, Tsutomu ; YOSHIDA, Seiichi ; ABE, Takashi ; NARITA, Miwako ; TAKAHASHI, Masuhiro</creator><creatorcontrib>YAMANAKA, Ryuya ; HOMMA, Junpei ; TANAKA, Ryuichi ; YAJIMA, Naoki ; TSUCHIYA, Naoto ; SANO, Masakazu ; KOBAYASHI, Tsutomu ; YOSHIDA, Seiichi ; ABE, Takashi ; NARITA, Miwako ; TAKAHASHI, Masuhiro</creatorcontrib><description>Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent
malignant glioma.
Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical
study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood
dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432,
and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally
every 3 weeks.
Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses
were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10
patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than
the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations
had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity
responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic
cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that
in the control group.
Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients
with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-05-0120</identifier><identifier>PMID: 15930352</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Cancer Vaccines - administration & dosage ; Cancer Vaccines - immunology ; Dendritic Cell ; Dendritic Cells - immunology ; Female ; Glioma ; Glioma - mortality ; Glioma - pathology ; Glioma - therapy ; Humans ; Immunotherapy ; Immunotherapy, Adoptive - methods ; Injections, Intradermal ; Injections, Intralesional ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local ; Neurology ; Pharmacology. Drug treatments ; Survival Rate ; Treatment Outcome ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Clinical cancer research, 2005-06, Vol.11 (11), p.4160-4167</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3</citedby><cites>FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16825060$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15930352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YAMANAKA, Ryuya</creatorcontrib><creatorcontrib>HOMMA, Junpei</creatorcontrib><creatorcontrib>TANAKA, Ryuichi</creatorcontrib><creatorcontrib>YAJIMA, Naoki</creatorcontrib><creatorcontrib>TSUCHIYA, Naoto</creatorcontrib><creatorcontrib>SANO, Masakazu</creatorcontrib><creatorcontrib>KOBAYASHI, Tsutomu</creatorcontrib><creatorcontrib>YOSHIDA, Seiichi</creatorcontrib><creatorcontrib>ABE, Takashi</creatorcontrib><creatorcontrib>NARITA, Miwako</creatorcontrib><creatorcontrib>TAKAHASHI, Masuhiro</creatorcontrib><title>Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent
malignant glioma.
Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical
study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood
dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432,
and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally
every 3 weeks.
Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses
were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10
patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than
the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations
had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity
responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic
cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that
in the control group.
Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients
with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - administration & dosage</subject><subject>Cancer Vaccines - immunology</subject><subject>Dendritic Cell</subject><subject>Dendritic Cells - immunology</subject><subject>Female</subject><subject>Glioma</subject><subject>Glioma - mortality</subject><subject>Glioma - pathology</subject><subject>Glioma - therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Injections, Intradermal</subject><subject>Injections, Intralesional</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqFkV1rFTEQhoNYbK3-BCU3Cl5sm8nXJt7JWuuBQkup3oY0m7iRnN2a7FoEf7xZzrG9LAQyyTzzTjIvQm-AnAAIdQqkVQ3hjJ503XVDREOAkmfoCIRoG0aleF7j_8whelnKT0KAA-Ev0CEIzQgT9Aj97VIco7MJn_22abFznEY8BfzZj32Oc3S48ynh79a5OO6yYcr4qoZ-nAu-j_OAr71bcq5nfJ7itLUf601ZUk1XJYsfWlwNtni8Od1s8E2ONr1CB8Gm4l_v92P07cvZTfe1ubg833SfLhonCMyNoD2oVhLL-zZQ0BqUF4wIC0py7RVl1AepAtNBAVeaB9ErLnmwraQt3LJj9H6ne5enX4svs9nG4uq_7OinpRjZKs00Z0-CoFtGKl1BsQNdnkrJPpi7HLc2_zFAzOqPWWdv1tmb6o8hwqz-1Lq3-wbL7db3j1V7Qyrwbg_YUkcWsh1dLI-cVFQQuQp92HFD_DHcx-yNq6SvLhRvsxvqI9bFobL_AP2SpPc</recordid><startdate>20050601</startdate><enddate>20050601</enddate><creator>YAMANAKA, Ryuya</creator><creator>HOMMA, Junpei</creator><creator>TANAKA, Ryuichi</creator><creator>YAJIMA, Naoki</creator><creator>TSUCHIYA, Naoto</creator><creator>SANO, Masakazu</creator><creator>KOBAYASHI, Tsutomu</creator><creator>YOSHIDA, Seiichi</creator><creator>ABE, Takashi</creator><creator>NARITA, Miwako</creator><creator>TAKAHASHI, Masuhiro</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20050601</creationdate><title>Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial</title><author>YAMANAKA, Ryuya ; HOMMA, Junpei ; TANAKA, Ryuichi ; YAJIMA, Naoki ; TSUCHIYA, Naoto ; SANO, Masakazu ; KOBAYASHI, Tsutomu ; YOSHIDA, Seiichi ; ABE, Takashi ; NARITA, Miwako ; TAKAHASHI, Masuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - administration & dosage</topic><topic>Cancer Vaccines - immunology</topic><topic>Dendritic Cell</topic><topic>Dendritic Cells - immunology</topic><topic>Female</topic><topic>Glioma</topic><topic>Glioma - mortality</topic><topic>Glioma - pathology</topic><topic>Glioma - therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Injections, Intradermal</topic><topic>Injections, Intralesional</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YAMANAKA, Ryuya</creatorcontrib><creatorcontrib>HOMMA, Junpei</creatorcontrib><creatorcontrib>TANAKA, Ryuichi</creatorcontrib><creatorcontrib>YAJIMA, Naoki</creatorcontrib><creatorcontrib>TSUCHIYA, Naoto</creatorcontrib><creatorcontrib>SANO, Masakazu</creatorcontrib><creatorcontrib>KOBAYASHI, Tsutomu</creatorcontrib><creatorcontrib>YOSHIDA, Seiichi</creatorcontrib><creatorcontrib>ABE, Takashi</creatorcontrib><creatorcontrib>NARITA, Miwako</creatorcontrib><creatorcontrib>TAKAHASHI, Masuhiro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YAMANAKA, Ryuya</au><au>HOMMA, Junpei</au><au>TANAKA, Ryuichi</au><au>YAJIMA, Naoki</au><au>TSUCHIYA, Naoto</au><au>SANO, Masakazu</au><au>KOBAYASHI, Tsutomu</au><au>YOSHIDA, Seiichi</au><au>ABE, Takashi</au><au>NARITA, Miwako</au><au>TAKAHASHI, Masuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2005-06-01</date><risdate>2005</risdate><volume>11</volume><issue>11</issue><spage>4160</spage><epage>4167</epage><pages>4160-4167</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent
malignant glioma.
Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical
study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood
dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432,
and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally
every 3 weeks.
Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses
were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10
patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than
the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations
had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity
responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic
cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that
in the control group.
Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients
with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15930352</pmid><doi>10.1158/1078-0432.CCR-05-0120</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2005-06, Vol.11 (11), p.4160-4167 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67893943 |
| source | Freely Accessible Journals |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Dendritic Cell Dendritic Cells - immunology Female Glioma Glioma - mortality Glioma - pathology Glioma - therapy Humans Immunotherapy Immunotherapy, Adoptive - methods Injections, Intradermal Injections, Intralesional Magnetic Resonance Imaging Male Medical sciences Middle Aged Neoplasm Recurrence, Local Neurology Pharmacology. Drug treatments Survival Rate Treatment Outcome Tumors of the nervous system. Phacomatoses |
| title | Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A16%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Evaluation%20of%20Dendritic%20Cell%20Vaccination%20for%20Patients%20with%20Recurrent%20Glioma:%20Results%20of%20a%20Clinical%20Phase%20I/II%20Trial&rft.jtitle=Clinical%20cancer%20research&rft.au=YAMANAKA,%20Ryuya&rft.date=2005-06-01&rft.volume=11&rft.issue=11&rft.spage=4160&rft.epage=4167&rft.pages=4160-4167&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-05-0120&rft_dat=%3Cproquest_cross%3E19730678%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c501t-52d18760a4d7f219918e5305a18649e8232ef68f39f814894f5d8464fa76271b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19730678&rft_id=info:pmid/15930352&rfr_iscdi=true |